Bcr-Abl kinase
BCR ABL kinase is dead; long live the CML stem cell
... of BCR-ABL kinase inhibition in CML stem cells or because CML stem cells do not require BCR-ABL for ...that BCR-ABL is kinase active in CML stem cells and that TKIs ...
5
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold
... against Abl kinase, the grafted peptides MTAbl06, MTAbl07, MTAbl13, and MTAbl15 showed no significant effect on the growth of K562 cells when administered at concentrations up to 64 μ ...reach ...
15
BCR ABL KINASE INHIBITORS FOR CANCER THERAPY
... tyrosine kinase inhibitors have started era of molecular targeted therapy and marked a greatest milestone in cancer drug ...tyrosine kinase activity of the BCR-ABL fusion protein has been ...
11
Sequential ABL kinase inhibitor therapy selects for compound drug resistant BCR ABL mutations with altered oncogenic potency
... with kinase inhibitors relates to the timing of ...first-generation ABL inhibitor imatinib (Gleevec), followed by the second-generation ABL inhibitor dasatinib (SPRYCEL) at time of resistance or ...
9
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
... existing Bcr-Abl kinase mutations to predict response to dasatinib and other second generation TKI, it may be possible to predict the probability of achieving CCyR using baseline clinical ...
12
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors
... tyrosine kinase inhibitor (TKI) approved by the Food and Drug Administration in 2001 is currently the first-line therapy for Ph + ...the BCR-ABL kinase domain point mutation is the most com- ...
8
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
... the BCR-ABL fusion oncogene which is detectable in over 90% of patients at pre- ...The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all phases of CML and is the standard ...
14
Bcr-abl Silencing by Specific Small-Interference RNA Expression Vector as a Potential Treatment for Chronic Myeloid Leukemia
... the Bcr-abl transcript was observed at 24 hours after transfection may be due to (a) the oligonucleotide degradation occurring under intracellular conditions and (b) a cell division was significantly ...
8
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
... 33 BCR-ABL kinase mutants (19–709 ...out BCR-ABL mutations, except for 2 patients with T315I mutation who exhibited marked resistance to ...
10
Applying the discovery of the Philadelphia chromosome
... the BCR-ABL tyrosine kinase causes ...the BCR-ABL kinase. Incorporating the use of markers of BCR-ABL kinase inhibition into clinical trials led to the ...
9
HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells
... The Bcr-Abl protein is an important client protein of heat shock protein 90 ...wild-type Bcr-Abl (b3a2, 32Dp210) and mutant Bcr-Abl imatinib (IM)-resistant cell ...with ...
11
Chronic Myeloid Leukemia: How to Overcome the Tyrosine Kinase Inhibitors Resistance
... inhibits BCR-ABL kinase activity by competing with ATP for the access to the ATP-binding pocket, thus locking BCR-ABL at the inactive conformation and preventing substrate ...
5
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities
... The t(9;22)(q34;q11) translocation juxtaposes the BCR and ABL1 genes in virtually all cases of CML and in a subset of adult/pediatric ALL. The latter may represent a de novo disease or, as in many adults, the ...
23
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
... the ABL TKI ...exhibit ABL TKI resistance have a poor prognosis, we have already reported our findings in these patients, particularly those resistant to ponatinib ...including ABL TKI-resistant ...
11
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
... Abbreviations: ALL, acute lymphoblastic leukemia; alloHCT, allogeneic hematopoietic cell transplantation; AP, accelerated phase; BP, blast phase; CCyR, complete cytogenetic response; CHR, complete hematologic response; ...
9
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
... of Bcr-Abl protein highlights a two-lobe catalytic domain: N- and C-lobes towards N- and C-terminus of the sequence, respectively ...the Bcr-Abl ...
14
Subcellular localization of Bcr, Abl, and Bcr Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation
... endogenous Bcr protein, as well as the aberrant p210BCR-ABL and p190BCR-ABL proteins consistently localize to the cytoplasm in both cell lines and fresh ...of Bcr-Abl proteins between ...
16
Masked inv dup(22)(q11.23), tetrasomy 8 and trisomy 19 in a blast crisis-chronic myeloid leukemia after interrupted Imatinib-treatment
... of BCR-ABL1 kinase domain, BCR-ABL1 amplifica- tion or enhanced expression rates, clonal evolution, and decrease in imatinib bioavailability or cell exposure ...
5
IGF-IR determines the fates of BCR/ABL leukemia
... the BCR/ ABL fusion oncogene [1-3]. Tyrosine kinase inhibitors (TKIs) effectively treat symptoms of CML patients, but the disease is not curable in most ...Both BCR/ABL dependent and ...
9
Pharmacogenetics and Molecular study on BCR/ABL Inhibitors connected with Chronic Myeloid Leukemia; Genotype variability polymorphism among Babylon population
... for BCR-ABL genes by selecting the clearest band which is 62 C°, PCR mixture was 5µl DNA, 5µl master mix, ...The BCR-ABL gene produce ...
5